115 related articles for article (PubMed ID: 38796380)
1. Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Uleri A; Baboudjian M; Diamand R; Ploussard G
Eur Urol; 2024 May; ():. PubMed ID: 38796380
[No Abstract] [Full Text] [Related]
2. Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Røder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Uleri A; Baboudjian M; Diamand R; Ploussard G
Eur Urol; 2024 May; ():. PubMed ID: 38796382
[No Abstract] [Full Text] [Related]
3. Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Vickers AJ
Eur Urol; 2024 May; ():. PubMed ID: 38797599
[No Abstract] [Full Text] [Related]
4. Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Stroomberg HV; Brasso K; Røder A
Eur Urol; 2024 May; ():. PubMed ID: 38749855
[No Abstract] [Full Text] [Related]
5. Reply to Giancarlo Marra, Marco Oderda, Paolo Gontero, and Lorenzo Richiardi's Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.12.015.
Hu JC; Allaf ME; Vickers AJ; Schaeffer EM
Eur Urol; 2024 Apr; ():. PubMed ID: 38599991
[No Abstract] [Full Text] [Related]
6. Reply to Benjamin Davies, Keith Kowalczyk RE: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.041.
Klaassen Z; Catto JWF; Vickers AJ; Cooperberg MR; Kutikov A
Eur Urol; 2022 Jul; 82(1):e12. PubMed ID: 35428508
[No Abstract] [Full Text] [Related]
7. Reply to Giancarlo Marra, Armando Stabile, Paolo Gontero, Francesco Montorsi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.11.019: A Storm in a Teacup.
Meissner VH; Gschwend JE; Heck MM
Eur Urol; 2022 May; 81(5):e117. PubMed ID: 35131117
[No Abstract] [Full Text] [Related]
8. Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.016.
Garcia-Ruiz A; Macarro C; Mateo J; Perez-Lopez R
Eur Urol; 2024 May; ():. PubMed ID: 38760292
[No Abstract] [Full Text] [Related]
9. Reply to Jinna Yao, Henry C.C. Pleass, and Howard M.H. Lau's Letter to the Editor re: Andrea Gallioli, Angelo Territo, Romain Boissier, et al. Learning Curve in Robot-assisted Kidney Transplantation: Results from the European Robotic Urological Society Working Group. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.008.
Gallioli A; Territo A; Breda A
Eur Urol; 2020 Jun; 77(6):e166-e167. PubMed ID: 32291108
[No Abstract] [Full Text] [Related]
10. Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
Chesnut GT; Vertosick EA; Ehdaie B
Eur Urol; 2020 Aug; 78(2):e65-e66. PubMed ID: 32386781
[No Abstract] [Full Text] [Related]
11. Re: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.041.
Davies B; Kowalczyk K
Eur Urol; 2022 Jul; 82(1):e11. PubMed ID: 35428507
[No Abstract] [Full Text] [Related]
12. Reply to Francesco Montorsi, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. Eur Urol 2021;80:567-72.
Vickers AJ
Eur Urol; 2021 Dec; 80(6):e149. PubMed ID: 34600778
[No Abstract] [Full Text] [Related]
13. Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012.
Kerkmeijer LGW; Pos FJ; van der Heide UA; Israël B; Draulans C; Haustermans K
Eur Urol; 2022 Jun; 81(6):e147-e148. PubMed ID: 35339319
[No Abstract] [Full Text] [Related]
14. Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
Feng M; Matoso A; Epstein G; Fong M; Park YH; Gabrielson A; Patel S; Czerniak B; Compérat E; Hoffman-Censits J; Kates M; Kim S; McConkey D; Choi W
Eur Urol; 2024 Apr; 85(4):e122-e123. PubMed ID: 37775361
[No Abstract] [Full Text] [Related]
15. Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag's Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
Valle LF; Kishan AU
Eur Urol; 2021 Jul; 80(1):e15-e16. PubMed ID: 33934928
[No Abstract] [Full Text] [Related]
16. Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.12.015.
Marra G; Oderda M; Gontero P;
Eur Urol; 2024 Mar; ():. PubMed ID: 38531702
[No Abstract] [Full Text] [Related]
17. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
Trock BJ; Karnes RJ
Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
[No Abstract] [Full Text] [Related]
18. Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038.
Rieken M; Shariat SF
Eur Urol; 2015 Nov; 68(5):e104-5. PubMed ID: 26314617
[No Abstract] [Full Text] [Related]
19. Reply to Behnam Shakiba's Letter to the Editor re: Emilien Seizilles de Mazancourt, Juliette Cotte, Caroline Plassais, et al. Sexual and Moral Harassment of French Urologists in Training and Barriers to Reporting: Results from a National Survey. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.10.020.
Seizilles de Mazancourt E; Kaulanjan K
Eur Urol; 2024 Feb; ():. PubMed ID: 38388257
[No Abstract] [Full Text] [Related]
20. Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.
Wilkinson S; Ye H; Lis RT; Sowalsky AG
Eur Urol; 2021 Sep; 80(3):e83-e84. PubMed ID: 34148711
[No Abstract] [Full Text] [Related]
[Next] [New Search]
